1. Home
  2. NMM vs GENB Comparison

NMM vs GENB Comparison

Compare NMM & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navios Maritime Partners LP

NMM

Navios Maritime Partners LP

HOLD

Current Price

$81.35

Market Cap

2.1B

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$14.05

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NMM
GENB
Founded
2007
2018
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
NMM
GENB
Price
$81.35
$14.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$85.00
$23.20
AVG Volume (30 Days)
93.1K
578.3K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
0.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.57
N/A
Revenue Next Year
$3.66
$16.58
P/E Ratio
$7.24
N/A
Revenue Growth
N/A
N/A
52 Week Low
$41.66
$11.00
52 Week High
$80.97
$18.18

Technical Indicators

Market Signals
Indicator
NMM
GENB
Relative Strength Index (RSI) 64.12 46.64
Support Level $69.21 $11.73
Resistance Level $80.69 $14.82
Average True Range (ATR) 2.50 0.78
MACD 0.53 -0.07
Stochastic Oscillator 79.97 64.59

Price Performance

Historical Comparison
NMM
GENB

About NMM Navios Maritime Partners LP

Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: